Command Palette

Search for a command to run...

Clinical Trials · NCT04387201

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

CompletedPhase 4Dulaglutide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
The University of Texas Health Science Center, Houston
Enrollment
23
Start date
May 2020
Locations
1 site, United States
Primary endpoint
Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue)
View Dulaglutide compound reference